A Phase I/II Trial: Docetaxel, Irinotecan, and Carboplatin in the Treatment of Extensive Stage Small Cell Lung Carcinoma
18 Years
N/A
Both
Non-small Cell Lung Cancer, Extensive Stage Unresectable
Trial Information
A Phase I/II Trial: Docetaxel, Irinotecan, and Carboplatin in the Treatment of Extensive Stage Small Cell Lung Carcinoma
A phase I/II dose escalating study to determine the maximum tolerated dose of docetaxel when
given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.
Inclusion Criteria:
- 18 years or older unresectable lung cancer measurable or evaluable lesions Karnofsky
PS greater than or equal to 60%
Exclusion Criteria:
- untreated CNS metastases
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.
Principal Investigator
Shawn Glisson, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Kentuckiana Cancer Institute
Authority:
United States: Institutional Review Board
Study ID:
1047791
NCT ID:
NCT00264134
Start Date:
June 2003
Completion Date:
October 2005
Related Keywords:
- Non-Small Cell Lung Cancer
- Extensive Stage Unresectable
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Small Cell Lung Carcinoma
Name | Location |
|---|---|
| Kentuckiana Cancer Institute | Louisville, Kentucky 40202 |
